Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Scholar Rock is anticipating a September 30 FDA decision for its investigational spinal muscular atrophy (SMA) drug, apitegromab. The drug, which targets latent myostatin, could be the first muscle-targeted therapy approved for SMA, and the company has resubmitted its application after resolving manufacturing observation issues with an alternate facility. Scholar Rock is also exploring the drug's potential for facioscapulohumeral muscular dystrophy (FSHD) and building commercial capabilities for a potential U.S. launch.
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock
Redmile Group, LLC, Jeremy C. Green, and RedCo II Master Fund, L.P. have filed an updated Schedule 13G/A, disclosing that Redmile and Green collectively report beneficial ownership of 4,311,092 shares of Scholar Rock common stock, representing 3.6% of the class. This ownership is held by investment vehicles managed by Redmile, with both Redmile and Green exercising shared voting and dispositive power. RedCo II Master Fund, L.P. reports 0 shares.
12 New Hires Receive 51,947 Scholar Rock Equity Awards
Scholar Rock (NASDAQ: SRRK) announced that it granted inducement equity awards totaling 51,947 shares of common stock to twelve new employees. These awards, which include both stock options and restricted stock units, are part of the company's 2022 Inducement Equity Plan, designed to attract new talent under Nasdaq Listing Rule 5635(c)(4). The grants aim to align new hires' interests with company performance while adhering to specific vesting schedules.
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00
JP Morgan maintained an "Overweight" rating for Scholar Rock Holding Corp (SRRK) and raised its price target from $56.00 to $63.00, indicating a positive outlook. Despite this, the company has a low GF Score™ of 29/100 due to profitability and growth concerns, along with significant insider selling. Investors are advised to exercise caution due to the high price-to-sales ratio and lack of intrinsic value data.
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares
Invus Public Equities, L.P. and associated entities have reported an 8.0% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,575,013 shares of common stock. This is detailed in an amended Schedule 13G filing, which states that the shares were acquired for passive investment purposes and not to influence control of Scholar Rock. The ownership calculation is based on 119,828,338 shares outstanding as of May 4, 2026.
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Scholar Rock Holding Corporation announced that the FDA review of its lead drug, apitegromab for spinal muscular atrophy, will proceed solely with its secondary fill-finish facility after an issue with its primary manufacturing site. Despite this change, the company confirmed that the Prescription Drug User Fee Act (PDUFA) action date of September 30 remains on schedule. Scholar Rock has secured a robust inventory from the alternative U.S.-based site to ensure supply readiness upon regulatory approval.
Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK
Bank of America Corp DE increased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 27.2% in the first quarter, adding 286,126 shares to hold a total of 1.34 million shares valued at approximately $65.7 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 91.08%. Despite some insider sales for tax obligations, analysts maintain a "Buy" consensus rating with an average price target of $56.79, as Scholar Rock reported quarterly EPS matching expectations.
SRRK Reiterated by Wedbush -- Maintains Price Target at $58.00
Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating for Scholar Rock Holding (SRRK) and maintained a $58.00 price target. Despite this, the company has a low GF Score™ of 29/100, indicating financial weaknesses, particularly in profitability and growth, and shows signs of potential overvaluation based on its high Price-to-Sales ratio and recent insider selling.
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush
Wedbush has reiterated an "Outperform" rating for Scholar Rock (SRRK) with a $58 price target, indicating a potential 12.45% upside. The company is near its 52-week high, and the analyst consensus remains "Buy" with an average target of $56.79. Institutional investors hold a significant stake, with recent insider sales primarily for tax obligations related to equity awards.
SRRK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65
HC Wainwright & Co. has reiterated its "Buy" rating for Scholar Rock Holding (SRRK), maintaining a price target of $65.00, suggesting a potential upside of 23% from its current price of $52.97. Despite this positive analyst outlook, the company has a low GF Score™ of 29/100, indicating underperformance, particularly in profitability, and insider activity shows $0.9 million in shares sold over the last three months. Investors are advised to exercise caution due to these mixed signals.
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History
This article provides a detailed overview of Scholar Rock Holding Corporation (SRRK), including its current stock price, financial data, and company profile. It highlights SRRK's focus on developing treatments for neuromuscular diseases and solid tumors, showcasing its key pipeline products and recent performance metrics compared to the S&P 500. The company's latest analyst ratings and financial statistics are also presented.
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Scholar Rock announced that the FDA review of its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) will proceed with a second fill-finish facility, following an Official Action Indicated (OAI) classification for their initial facility, Catalent Indiana. The company expects a potential FDA approval by the September 30, 2026, PDUFA action date, with a robust commercial supply ready for packaging. Scholar Rock is also engaging with the European Medicines Agency (EMA) regarding the inclusion of this second facility in their Marketing Authorisation Application (MAA).
Form 8K Scholar Rock Holding Corp For: 6 August By Investing.com
This article briefly reports on the filing of Form 8K by Scholar Rock Holding Corp for August 6. It mentions the company's stock symbol, SRRK, and includes a minor positive percentage change in its stock value. The content is primarily a placeholder for the SEC filing itself.
Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates
Scholar Rock (NASDAQ:SRRK) reported quarterly earnings of ($0.84) per share, meeting analyst estimates, an improvement from ($0.98) per share a year ago. The company's U.S. approval for apitegromab is still targeted for September 30, despite delays in European approval due to FDA classification uncertainties regarding a Catalent Indiana facility. Scholar Rock ended the quarter with $492 million in liquidity and saw its shares rise by 10% following the results.
Scholar Rock Holding Corp 2Q 2026: Net loss $(215.4M), EPS $(1.67) — 10-Q Summary
Scholar Rock Holding Corp (SRRK) reported a consolidated net loss of $(215.4M) for the six months ended June 30, 2026, with a basic and diluted loss per share of $(1.67). The company recorded no product or commercial sales revenue during this period. Key business highlights include the FDA's acceptance of a resubmitted BLA for apitegromab with a PDUFA date of September 30, 2026, positive Phase 3 SAPPHIRE results for non-ambulatory SMA, and ongoing investment in commercial infrastructure for a potential product launch.
Earnings call transcript: Scholar Rock tops Q2 2026 EPS view, shares rise premarket
Scholar Rock reported better-than-expected Q2 2026 earnings per share and confirmed its lead drug apitegromab is on track for a U.S. regulatory decision by September 30, leading to a premarket stock increase. The company highlighted its readiness for launch with a second fill-finish facility and a strong financial position, while also advancing its anti-myostatin pipeline. Executives expressed confidence in the FDA review process and their commercial preparedness for both U.S. and European markets.
Scholar Rock Q2 2026 Earnings Call Transcript
Scholar Rock provided its Q2 2026 earnings update, highlighting that U.S. approval for apitegromab remains on track for September 30th despite regulatory uncertainty regarding the Catalent Indiana facility. The company has secured an independent second fill-finish facility, whose data package has been submitted to the FDA and is progressing well. Commercial launch preparations are advanced in the U.S. and Europe, with significant financial strength to support these initiatives and continued development of their anti-myostatin pipeline.
Scholar Rock files $200 million at-the-market offering prospectus with SEC
Scholar Rock Holding Corporation has filed a prospectus supplement for a $200 million at-the-market (ATM) offering of common stock, replacing a previous offering. The biotech company, valued at $5.74 billion and up 38% in the past year, has already raised $257.7 million through its ATM program. Despite being unprofitable, its liquid assets exceed short-term obligations, though InvestingPro views the stock as overvalued.
The Bull Case For Scholar Rock (SRRK) Could Change Following Dual-Track Apitegromab BLA Manufacturing Strategy
Scholar Rock (SRRK) reported Q2 2026 results, showing a net loss but significant progress on its apitegromab program for SMA. The company is pursuing a dual-track Biologics License Application strategy with two independent fill-finish facilities, aiming for FDA approval by September 2026 and preparing for immediate U.S. launch. This strategy aims to enhance reliability and potentially expedite approval, though regulatory and inspection risks remain.
Form 8K Scholar Rock Holding Corp For: 6 August By Investing.com
This article announces the filing of a Form 8K by Scholar Rock Holding Corp for August 6th. The brief piece includes the stock symbol SRRK and notes a significant price increase of 9.96%. The content primarily consists of market data and news headlines rather than detailed information about the Form 8K itself.
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock announced its second-quarter 2026 financial results, highlighting ongoing FDA review for its Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA), with a potential approval by September 30, 2026. The company also initiated a Phase 2 trial for apitegromab in facioscapulohumeral muscular dystrophy (FSHD) and reported $492 million in cash, cash equivalents, and marketable securities. Scholar Rock is prepared for a U.S. launch of apitegromab immediately upon FDA approval, reinforcing its commitment to neuromuscular disease treatments.
Scholar Rock Holding Corp (SRRK) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Scholar Rock Holding Corp (SRRK), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of the analysis, the stock's price momentum score is 4.07, and it is trading between resistance at 54.32 and support at 41.56. The article notes a "Neutral" signal based on moving averages and other technical indicators for the stock.
Scholar Rock Holding Corp (SRRK) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Scholar Rock Holding Corp (SRRK), highlighting its current earnings forecast score of 8.78 within the Biotechnology & Medical Research industry. It details analyst ratings, target prices, and revenue expectations, indicating a generally positive outlook with most analysts recommending a "Buy". The report also includes peer comparisons and answers frequently asked questions regarding the company's financial performance.
Scholar Rock Sets Aug. 12 Webcast From Boston Growth Conference
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. The presentation is scheduled for Wednesday, August 12, 2026, at 1:30 p.m. ET. A live webcast and replay of the event will be available on the Investors section of the company's website.
Scholar Rock Holding Corp (SRRK) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Scholar Rock Holding Corp (SRRK), giving it a current financial score of 6.32, ranking 264 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable, but its operating efficiency is low. The report indicates that relevant financial data regarding quality of earnings, operational efficiency, growth potential, and shareholder returns have not yet been disclosed by the company.
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Kuehn Law, PLLC is investigating Scholar Rock Holding Corp (NASDAQ: SRRK) for potential breaches of fiduciary duties by its officers and directors, specifically concerning alleged self-dealing. The law firm is encouraging long-term SRRK shareholders to contact them to explore potential damages and corporate governance reforms, offering free consultations and covering case costs. They emphasize that shareholder participation is crucial for maintaining integrity in financial markets.
Investigation launched into Scholar Rock officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has launched an investigation into certain officers and directors of Scholar Rock Holding Corp, suspecting they may have breached their fiduciary duties through self-dealing. This probe aims to determine if shareholders have been harmed and could lead to compensation and corporate governance reforms. Long-term shareholders are encouraged to seek a free consultation to protect their rights.
SRRK|Scholar Rock Holding Corp|Price:47.750|Chg%:-1.180
The article provides a comprehensive stock analysis of Scholar Rock Holding Corp (SRRK), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation. It notes strong institutional ownership and a "Buy" rating from multiple analysts with a target price suggesting significant upside. Despite recent weak market performance, the company's strong fundamentals and sideways trading pattern indicate suitability for range-bound swing trading.
Scholar Rock Holding Corp (SRRK) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Scholar Rock Holding Corp (SRRK), listing major institutional shareholders and their proportional holdings. It also breaks down shareholder types, institutional shareholding trends over several quarters, and provides information on related ETFs that hold SRRK. The data indicates significant institutional investment and recent changes in share ownership.
Scholar Rock Holding Corp (SRRK) Cash Flow
This article provides a detailed cash flow statement for Scholar Rock Holding Corp (SRRK), including quarterly and annual data for operating, investing, and financing activities. It presents financial figures along with year-over-year percentage changes for various cash flow components. The article also includes a FAQ section defining different types of cash flow and highlighting SRRK's recent performance in these areas.
SRRK Reiterated by Wedbush -- Price Target Maintained at $58
Wedbush analyst David Nierengarten has reiterated an "Outperform" rating for Scholar Rock Holding (SRRK), maintaining a price target of $58.00. Despite this positive outlook, the company has a low GF Score™ of 30/100 and has seen $0.9 million in insider selling over the past three months, raising potential red flags for investors. Scholar Rock Holding operates in the biotechnology sector, specializing in therapies for rare neuromuscular diseases, and is currently trading at $50.75.
Law firm investigates Scholar Rock officers for possible shareholder duty breaches
Kuehn Law, PLLC is investigating Scholar Rock Holding Corp (NASDAQ: SRRK) officers and directors for potential breaches of fiduciary duties and self-dealing, which could entitle shareholders to damages and governance reforms. The firm is urging long-term investors to come forward promptly to protect their rights and ensure market fairness. This investigation highlights concerns about corporate governance and shareholder protection at Scholar Rock.
SMA treatment review in Europe awaits FDA facility classification
Scholar Rock is awaiting a CHMP opinion on its apitegromab marketing authorization application (MAA) for spinal muscular atrophy (SMA) in Europe. The decision is contingent on the FDA's inspection classification of the Catalent Indiana fill-finish facility, included in the MAA. If not reclassified, Scholar Rock plans to utilize a second U.S.-based fill-finish facility, which is already part of its U.S. Biologics License Application.
11 New Hires Get Scholar Rock Equity Awards Covering 118,586 Shares
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards totaling 118,586 shares of its common stock to eleven new employees. These awards consist of stock options for 33,987 shares and restricted stock units for 84,599 shares, granted under the company's 2022 Inducement Equity Plan as per Nasdaq Listing Rule 5635(c)(4). The grants are designed to incentivize new hires, with vesting schedules tied to continued employment and an exercise price for the options set at $54.70.
Scholar Rock (SRRK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Scholar Rock presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its lead asset, apitegromab, a late-stage myostatin inhibitor for SMA, with regulatory filings underway and anticipated launches in 2026. The company plans to commercialize apitegromab in up to 50 countries and is also developing it for FSHD, with a Phase II trial starting later in the year. Scholar Rock is also advancing a subcutaneous version of apitegromab and a new molecular entity, SRK-439, into clinical development.
Scholar Rock (SRRK) Q3 2025 earnings summary
Scholar Rock's Q3 2025 earnings show a net loss of $102.2 million, up from the previous year. The delay in apitegromab's U.S. approval for SMA is attributed to manufacturing compliance issues at a third-party facility, not efficacy or safety. The company is actively working to resolve these issues, including securing commercial capacity for Q1 2026 and advancing its pipeline projects.
Scholar Rock schedules Aug. 6 webcast before markets open
Scholar Rock (NASDAQ: SRRK) announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026, before market open. The company will host a conference call and webcast with management at 8:00 a.m. ET. Interested parties can access the live audio webcast via the Investors section of Scholar Rock’s website.
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH
Several biotech stocks, including American Well Corporation (AMWL), Cue Biopharma Inc. (CUE), ImmuCell Corporation (ICCC), Scholar Rock Holding Corp. (SRRK), and Faeth Therapeutics Inc. (FTH), reached 52-week highs on July 10, 2026. These gains were propelled by various catalysts such as positive regulatory updates, encouraging clinical trial progress, and strong quarterly financial results. The article details the specific advances and financial outlook for each company.
Scholar Rock (SRRK) Q1 2025 earnings summary
Scholar Rock (SRRK) reported a Q1 2025 net loss of $74.7 million, up from $56.9 million in Q1 2024, with no revenue. The company is advancing its lead drug, apitegromab, which achieved positive Phase 3 results in SMA and is set for FDA priority review with a U.S. launch anticipated in Q3 2025. Scholar Rock ended Q1 2025 with $364.4 million in cash, projecting a cash runway through 2027, and is also expanding its pipeline with other neuromuscular disorder studies and an obesity trial.
Scholar Rock stock hits 52-week high at 56.56 USD
Scholar Rock Holding Corp (SRRK) stock reached a new 52-week high of $56.56, marking a 56% 1-year return and reflecting strong investor confidence despite its stock potentially being overvalued according to InvestingPro. Analysts maintain a "Strong Buy" rating with price targets between $48 and $70. The company recently reported Q1 2026 earnings, slightly missing EPS forecasts, but saw its stock rise due to product development progress, including the resubmission of its biologics license application for apitegromab.
Scholar Rock (SRRK) director Katie Peng sells 5,446 shares under 10b5-1 tax plan
Scholar Rock Holding Corp director Katie Peng sold 5,446 shares of common stock on July 1, 2026, under a Rule 10b5-1 trading plan. The sales, totaling $293,405, were executed to cover tax obligations arising from the vesting of restricted stock units. Following these transactions, Peng maintains a significant stake with 21,500 shares of common stock and 12,801 RSUs.
Form 144 Scholar Rock Holding Corp. For: 6 July By Investing.com
This article announces the filing of Form 144 for Scholar Rock Holding Corp. on July 6. Form 144 is a notice of the intent to sell restricted securities, typically filed by company insiders. The article indicates that full details can be found on Investing.com.
Mohammed Qatanani to sell 11,704 SRRK shares (NASDAQ: SRRK)
Mohammed Qatanani has filed a Form 144 indicating a proposed sale of 11,704 shares of Scholar Rock Holding Corp (NASDAQ: SRRK) common stock. This sale is planned for July 6, 2026, through a stock option exercise, with J.P. Morgan Securities LLC as the broker. The filing also notes a prior sale of 11,704 shares on April 6, 2026, within the last three months.
Scholar Rock (NASDAQ: SRRK) director 10b5-1 sale of 3,053 shares
Scholar Rock Holding Corp director Jeffrey S. Flier sold 3,053 shares of common stock on July 1, 2026, through a Rule 10b-5-1 trading plan. These sales, executed at weighted average prices between $52.96 and $55.01 per share, were primarily to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Flier retains a significant stake in Scholar Rock, holding 21,017 shares of common stock and 6,839 restricted stock units.
Insider at Scholar Rock (SRRK) sells 2,544 shares under 10b5-1 plan
Michael Gilman, a Director at Scholar Rock Holding Corp (SRRK), sold 2,544 shares of common stock on July 1, 2026, under a pre-arranged 10b5-1 trading plan. The sales, executed at weighted average prices between $52.97 and $55.01 per share, were made to cover tax obligations from the vesting of restricted stock units (RSUs). Following these transactions, Gilman still holds a significant stake of 52,672 shares and 6,839 RSUs in the company.
SRRK - Scholar Rock Holding Corp Volatility & Greeks
This article provides a detailed financial overview of Scholar Rock Holding Corp (SRRK), including its volatility, key financial metrics, stock performance, and analyst recommendations. It highlights the company's market capitalization, income, sales, and various ratios, alongside insider and institutional ownership data.
[144] Scholar Rock Holding Corp SEC Filing
This article details a Form 144 SEC filing by Scholar Rock Holding Corp (SRRK) concerning a proposed sale of securities. The filing indicates a neutral impact and sentiment, outlining the sale of 3,053 shares of common stock with an aggregate market value of $167,274 through J.P. Morgan Securities LLC on July 1, 2026. The shares were acquired via RSU from the Issuer on June 5, 2026.
SRRK (NASDAQ: SRRK) files Rule 144 notice to sell 5,446 shares via J.P. Morgan
Scholar Rock Holding Corp (SRRK) has filed a Rule 144 notice indicating an intention to sell 5,446 common shares through J.P. Morgan Securities LLC. These shares are related to RSU settlements scheduled for February 15, 2026 (261 shares), March 15, 2026 (745 shares), and June 15, 2026 (4,440 shares). The filing acts as a disclosure of planned sales under resale exemptions, rather than a confirmation of completed transactions.
Form 144 Scholar Rock Holding Corp. For: 1 July By Investing.com
This article announces the filing of Form 144 for Scholar Rock Holding Corp. on July 1st, as reported by Investing.com. The content itself is very brief and primarily serves as a placeholder for the news of this specific financial filing.
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Analysts
Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus "Buy" recommendation from 17 analysts, with an average 1-year price target of $56.00. While some recent analyst updates included price target increases, Weiss Ratings reiterated a "sell" rating. The stock traded near its 52-week high after reporting a quarterly loss of ($0.83) per share, and insider selling occurred due to tax withholdings on equity awards.
